We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
-2.4%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.32B
AUM Growth
-$216M
Cap. Flow
-$62.5M
Cap. Flow %
-1.18%
Top 10 Hldgs %
23.94%
Holding
294
New
29
Increased
89
Reduced
98
Closed
32

Top Buys

Rank Stock Value
1
UNP icon
Union Pacific
UNP
+$46.6M
2
GILD icon
Gilead Sciences
GILD
+$37M
3
BCR
CR Bard Inc.
BCR
+$31.1M
4
CVS icon
CVS Health
CVS
+$27.8M
5
DHR icon
Danaher
DHR
+$26.6M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$36.5M
2
PNC icon
PNC Financial Services
PNC
+$34.3M
3
CELG
Celgene Corp
CELG
+$32.4M
4
AGN
Allergan plc
AGN
+$28M
5
CNC icon
Centene
CNC
+$27.3M

Sector Composition

Rank Sector Weight
1 Technology 24.2%
2 Healthcare 23.21%
3 Financials 21.91%
4 Communication Services 9.94%
5 Industrials 5.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTSH icon
251
Cognizant
CTSH
$23.8B
– –
-73,619
Closed -$4.42M
CWEN.A
252
DELISTED
Clearway Energy Class A
CWEN.A
– –
-20,342
Closed -$283K
HAL icon
253
Halliburton
HAL
$26.1B
– –
-592,780
Closed -$20.2M
HALO icon
254
Halozyme
HALO
$9.9B
– –
-30,649
Closed -$531K
ILMN icon
255
Illumina
ILMN
$29.2B
– –
-49,896
Closed -$9.32M
IONS icon
256
Ionis Pharmaceuticals
IONS
$9.14B
– –
-8,727
Closed -$540K
LSAK icon
257
Lesaka Technologies
LSAK
$392M
– –
-19,593
Closed -$265K
MD icon
258
Pediatrix Medical
MD
$2.21B
– –
-225,000
Closed -$16.1M
PB icon
259
Prosperity Bancshares
PB
$8.82B
– –
-8,682
Closed -$416K
PRQR icon
260
ProQR Therapeutics
PRQR
$248M
– –
-30,000
Closed -$260K
SABR icon
261
Sabre
SABR
$743M
– –
-67,698
Closed -$1.89M
TCOM icon
262
Trip.com Group
TCOM
$28.5B
– –
-174,933
Closed -$8.1M
WT icon
263
WisdomTree
WT
$2.97B
– –
-14,950
Closed -$234K
TWOU
264
DELISTED
2U Inc
TWOU
– –
-2,819
Closed -$2.36M
VMW
265
DELISTED
VMware, Inc
VMW
– –
-172,872
Closed -$9.78M
ICPT
266
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-13,921
Closed -$2.08M
SC
267
DELISTED
SANTANDER CONSUMER USA HOLDINGS INC
SC
– –
-26,348
Closed -$418K
IPHI
268
DELISTED
INPHI CORPORATION
IPHI
– –
-84,626
Closed -$2.29M
PTLA
269
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-520,000
Closed -$26.8M
MDCO
270
DELISTED
Medicines Co
MDCO
– –
-233,986
Closed -$8.74M
AGU
271
DELISTED
Agrium
AGU
– –
-12,500
Closed -$1.12M
TMH
272
DELISTED
Team Health Holdings Inc
TMH
– –
-181,586
Closed -$7.97M
QIWI
273
DELISTED
QIWI PLC
QIWI
– –
-17,317
Closed -$311K
CY
274
DELISTED
Cypress Semiconductor
CY
– –
-413,776
Closed -$4.06M
SHPG
275
DELISTED
Shire pic
SHPG
– –
-6,823
Closed -$1.4M
8 9 10
11
12

Similar funds

ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Polar Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Polar Capital held 294 positions worth $5.32B, down 3.9% from $5.53B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Polar Capital's Q1 2016 filing shows 29 new, 89 increased, 98 reduced and 32 closed positions. Its largest new stake was Union Pacific: 603,004 shares worth $48M. The largest sale was Bristol-Myers Squibb, an estimated $36.5M.

By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.

  • Polar Capital's largest Q1 2016 buy was Union Pacific: 603,004 shares worth $48M.
  • Polar Capital added most to Gilead Sciences in Q1 2016, an estimated $37M increase.
  • Polar Capital's biggest Q1 2016 reduction was Bristol-Myers Squibb, cutting an estimated $36.5M.
  • Polar Capital fully exited Centene in Q1 2016, selling an estimated $27.3M.
  • Polar Capital's ten largest holdings make up 24% of its $5.32B portfolio in Q1 2016.
  • Polar Capital opened 29 new positions and closed 32 in Q1 2016.
  • Polar Capital's portfolio value fell 3.9% quarter-over-quarter to $5.32B.

Based on Polar Capital's 13F filing for Q1 2016, filed 16 May 2016.